Becenun en es it fr

Becenun Brand names, Becenun Analogs

Becenun Brand Names Mixture

  • No information avaliable

Becenun Chemical_Formula


Becenun RX_link

Becenun fda sheet

Becenun msds (material safety sheet)

Becenun MSDS

Becenun Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Becenun Molecular Weight

214.049 g/mol

Becenun Melting Point

31 oC

Becenun H2O Solubility

< 0.1 g/100 mL at 18 °C

Becenun State


Becenun LogP


Becenun Dosage Forms

Powder for solution; Wafer

Becenun Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Becenun Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Becenun Absorption

5 to 28% bioavailability

Becenun side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Becenun Patient Information

No information avaliable

Becenun Organisms Affected

Humans and other mammals